保肾口服液治疗IgA肾病小鼠的实验研究  

Experimental Study on Therapeutic Effect of Kidney Protection Liquid on IgA Nephropathy rat model

作　　者：吴竞[1] 杨爱国[1] 阮诗纬[1] 王智[1] 洪江淮[1] 丘余良[1] 

机构地区：[1]福建省人民医院肾内科,福建福州350004

出　　处：《中医药学刊》2005年第11期1982-1985,共4页Study Journal of Traditional Chinese Medicine

基　　金：福建省卫生厅资助项目(0781)

摘　　要：目的探讨保肾口服液对实验性IgA肾病小鼠的作用机理。方法采用口服牛血清白蛋白及静注葡萄糖球菌肠毒素制成的小鼠IgA肾病模型,分析保肾口服液的作用机理。结果保肾口服液大剂量组对降低小鼠尿红细胞计数最为明显;小鼠血清IgA含量组间比较未见显著性统计学差异;3个剂量的保肾口服液治疗组比潘生丁治疗组肾组织IgA荧光强度弱,潘生丁治疗组比肾炎康复片组肾组织IgA荧光强度弱。3个剂量的保肾口服液组IgA荧光强度比较未见明显变化;5个治疗组肾小球轻度增大,系膜细胞和系膜基质增生的程度较病理组均轻,系膜细胞数较病理组少,毛细血管管腔受压不明显。结论保肾口服液能降低IgA肾病小鼠尿红细胞,减少肾组织中IgA的沉积,抑制系膜细胞和系膜基质的增生。Objection：To evaluate the mechanism of KPL on experimental IgA Nephropathy rat model. Methods：To study the mechanism of KPL, the IgA Nephropathy rat model was copied by the methods of oral taking BSA and vein injection of SEB. Results ：The large dosage KPL group had significant function of reducing the urine RBC and IgA immunofluorescence; density of the KPL groups was lower than Persantine group. There is no obvious difference among the 3 KPL groups in IgA immunofluorescence. The Kidney biopsy damage of glomerulus, measagnial cell, mesangial matrix cell among 5 Treatment group was mild. Conclusion ：The KPL can reduce the microscopic heamaturia and deposits of the protein immunoglobulin A inside the glomeruli within the kindney.

关 键 词：保肾口服液 IGA肾病 实验研究 

分 类 号：R285.5[医药卫生—中药学]